Bafna Pharmaceuticals Ltd vs Sms Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Bafna Pharmaceuticals Ltd is ₹ 135.7 as of 30 Apr 15:30 . The P/E Ratio of Bafna Pharmaceuticals Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of SMS Pharmaceuticals Ltd changed from 16.8 on March 2021 to 27.3 on March 2025 . This represents a CAGR of 10.20% over 5 years The Market Cap of Bafna Pharmaceuticals Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of SMS Pharmaceuticals Ltd changed from ₹ 1053 crore on March 2021 to ₹ 1885 crore on March 2025 . This represents a CAGR of 12.36% over 5 years The revenue of Bafna Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of SMS Pharmaceuticals Ltd for the Dec '25 is ₹ 214.2 crore as compare to the Sep '25 revenue of ₹ 243.86 crore. This represent the decline of -12.16% The ebitda of Bafna Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of SMS Pharmaceuticals Ltd for the Dec '25 is ₹ 47.4 crore as compare to the Sep '25 ebitda of ₹ 49.8 crore. This represent the decline of -4.82% The net profit of Bafna Pharmaceuticals Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of SMS Pharmaceuticals Ltd changed from ₹ 16.37 crore to ₹ 23.19 crore over 7 quarters. This represents a CAGR of 22.02% The Dividend Payout of Bafna Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of SMS Pharmaceuticals Ltd changed from 4.17 % on March 2021 to 5.19 % on March 2025 . This represents a CAGR of 4.47% over 5 years .

About Bafna Pharmaceuticals Ltd

Bafna Pharmaceuticals Limited (BPL) was started as a proprietary concern in 1981 by Mr. Bafna Mahaveer Chand in the name of Bafna Pharmaceutical and is engaged in the manufacturing of pharmaceutical formulations of Betalactum and Non Betalactum products.
The first manufacturing unit was set up at Madhavaram (Chennai) during October 1984 for manufacture of tablets with an installed capacity of 420 lacs tablets p.a.
Subsequently the capsule line was added during 1987 with a capacity of 300 lacs capsule p.a. and then liquid line with an installed capacity of 45000 lts p.a was added in 1990. Bafna Pharmaceuticals, incorporated in 1995, had acquired the entire business of the proprietary concern.
During the year 2001, the company constructed a separate block at Madhavaram for manufacturing Betalactum products.

About SMS Pharmaceuticals Ltd

SMS Pharmaceuticals Limited was incorporated in December, 1987.
The company is engaged in the business of manufacturing of Active Pharma Ingredients and their intermediates.
Apart from R &D Center at Gagillapur, Hyderabad, the company is having manufacturing facilities at Bachupally, Hyderabad and also at Kandivalasa Village in Vijayanagaram District of Andhra Pradesh. During the year 2015, the company has re-enforced its fundamental strength of FDA compliant facilities by successfully completing the US FDA audits at Kandivalasa and Bachupally facilities. During the year 2015, the company filed 9 Drug Master Files and total DMFs filed up to 31 March 2015 are 24. During the year 2014-15, the Company acquired 12,25,900 equity shares of Rs. 10/- each in M/s.
VKT Pharma Private Limited.

FAQs for the comparison of Bafna Pharmaceuticals Ltd and SMS Pharmaceuticals Ltd

Which company has a larger market capitalization, Bafna Pharmaceuticals Ltd or SMS Pharmaceuticals Ltd?

Market cap of Bafna Pharmaceuticals Ltd is 321 Cr while Market cap of SMS Pharmaceuticals Ltd is 3,788 Cr

What are the key factors driving the stock performance of Bafna Pharmaceuticals Ltd and SMS Pharmaceuticals Ltd?

The stock performance of Bafna Pharmaceuticals Ltd and SMS Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bafna Pharmaceuticals Ltd and SMS Pharmaceuticals Ltd?

As of May 3, 2026, the Bafna Pharmaceuticals Ltd stock price is INR ₹135.7. On the other hand, SMS Pharmaceuticals Ltd stock price is INR ₹404.55.

How do dividend payouts of Bafna Pharmaceuticals Ltd and SMS Pharmaceuticals Ltd compare?

To compare the dividend payouts of Bafna Pharmaceuticals Ltd and SMS Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.